Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bristol-Myers Squibb Co. (NYSE: BMY).

Full DD Report for BMY

You must become a subscriber to view this report.


Recent News from (NYSE: BMY)

Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York. Giovanni Caforio, M.D. , chairman and chief executive officer will make formal remarks about the company and answer questions at 11...
Source: Business Wire
Date: September, 06 2018 15:00
Bristol-Myers Squibb And NASH: Where Do We Stand?
If you think education is expensive, try ignorance - Derek Bok Investment Thesis Bristol-Myers Squibb Company ( BMY ) is a multi-billion ($99B) large market cap global biopharmaceutical company defined by its revolutionary therapeutics for cancer, autoimmunity, HIV, and HCV inf...
Source: SeekingAlpha
Date: September, 06 2018 09:18
Iovance Bio down 12% premarket following corporate presentation
Iovance Biotherapeutics (NASDAQ: IOVA ) slumps  12%  premarket on increased volume on the heels of a presentation at the H.C. Wainwright Global Investor Conference in New York City yesterday. More news on: Iovance Biotherapeutics, Inc., Bristol-Myers Squibb Company, Healthcare st...
Source: SeekingAlpha
Date: September, 06 2018 08:39
Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2018 on Thursday, October 25, 2018. During a conference call at 10:30 a.m. EDT on October 25, company executives will review financial information and will address inquiries from investors and analysts. ...
Source: Business Wire
Date: September, 06 2018 06:59
Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Compugen, 'From Code To Cure': Becoming A Clinical-Stage Company
With a market cap of only $225 million (including $43 million in cash as of June 30th), Compugen Ltd. ( CGEN ) has the potential to deliver outsized returns for shareholders over the next 12 to 24 months. Since publishing my initial article on Compugen on SA on February 20, 2018, Compugen ...
Source: SeekingAlpha
Date: September, 05 2018 10:11
Nektar: A Rare Opportunity For Long-Term Investors
Basing a strategy on general maxims, such as “sell when you double your money, “sell after two years,” or “cut your losses by selling when the price falls 10 percent” is absolute folly. It’s simply impossible to find a generic formula that sensibly ...
Source: SeekingAlpha
Date: September, 04 2018 19:36
Sutro Biopharma Begins U.S. IPO Effort
Quick Take Sutro Biopharma ( STRO ) intends to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The clinical stage biopharmaceutical company develops protein cancer therapeutics by using OCFS protein synthesis technology. STRO is ...
Source: SeekingAlpha
Date: September, 04 2018 13:40
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516...
Source: SeekingAlpha
Date: September, 01 2018 05:42
Big Pharma in the red after AstraZeneca lupus flop
Big Pharma is getting roughed up today. This morning, AstraZeneca ( AZN -1.7% ) announced that one of its main drivers of expected future growth failed a late-stage lupus study. More news on: AstraZeneca Group plc, Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks ne...
Source: SeekingAlpha
Date: August, 31 2018 13:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0860.7261.3161.414260.643,519,916
2018-05-1752.0552.7453.4051.968,097,423
2017-11-0761.5861.9162.4361.454,047,238
2017-11-0662.2461.6862.2761.284,222,569
2017-11-0362.0862.2262.2561.7953,327,317

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14112,549271,07441.5197Short
2018-12-13121,450324,23937.4569Short
2018-12-1248,103269,64517.8394Cover
2018-12-1158,564339,39717.2553Cover
2018-12-10190,659521,24436.5777Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BMY.


About Bristol-Myers Squibb Co. (NYSE: BMY)

Logo for Bristol-Myers Squibb Co. (NYSE: BMY)

Not available

 

Contact Information

 

 

Current Management

  • Sandra Leung / Secretary

Current Share Structure

  • Market Cap: $84,767,164,432 - 05/11/2018
  • Issue and Outstanding: 1,634,538,458 - 03/31/2018

 


Recent Filings from (NYSE: BMY)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 22 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NYSE: BMY)

Daily Technical Chart for (NYSE: BMY)


Stay tuned for daily updates and more on (NYSE: BMY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: BMY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BMY and does not buy, sell, or trade any shares of BMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/